These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 6211142

  • 1. In vitro activity of MK-0366 against clinical urinary pathogens including gentamicin-resistant Pseudomonas aeruginosa.
    Downs J, Andriole VT, Ryan JL.
    Antimicrob Agents Chemother; 1982 Apr; 21(4):670-2. PubMed ID: 6211142
    [Abstract] [Full Text] [Related]

  • 2. Comparative in vitro activity of norfloxacin (MK-0366) and ten other oral antimicrobial agents against urinary bacterial isolates.
    Khan MY, Gruninger RP, Nelson SM, Klicker RE.
    Antimicrob Agents Chemother; 1982 May; 21(5):848-51. PubMed ID: 6213200
    [Abstract] [Full Text] [Related]

  • 3. Comparative in vitro activities of norfloxacin (MK-0366) and six commonly used antimicrobial agents against 199 urinary isolates showing various degrees of antibiotic resistance.
    Corigliano BE, Appleman MD, Heseltine PN, Leedom JM.
    Diagn Microbiol Infect Dis; 1984 Apr; 2(2):101-6. PubMed ID: 6232085
    [Abstract] [Full Text] [Related]

  • 4. Comparative activities of norfloxacin and fifteen other antipseudomonal agents against gentamicin-susceptible and -resistant Pseudomonas aeruginosa strains.
    Forward KR, Harding GK, Gray GJ, Urias BA, Ronald AR.
    Antimicrob Agents Chemother; 1983 Oct; 24(4):602-4. PubMed ID: 6228193
    [Abstract] [Full Text] [Related]

  • 5. Study of the in vitro activity of norfloxacin and other drugs on amoxicillin-resistant uropathogenic isolates.
    Piccolomini R, Allocati N, Catamo G.
    Chemioterapia; 1984 Jun; 3(3):167-72. PubMed ID: 6241505
    [Abstract] [Full Text] [Related]

  • 6. Norfloxacin: in vitro activity compared with that of seven other antibacterial agents against urinary tract pathogens.
    Digranes A, Dibb WL, Ostervold B.
    Acta Pathol Microbiol Immunol Scand B; 1984 Apr; 92(2):101-6. PubMed ID: 6233841
    [Abstract] [Full Text] [Related]

  • 7. In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim.
    Neu HC, Labthavikul P.
    Antimicrob Agents Chemother; 1982 Jul; 22(1):23-7. PubMed ID: 6214995
    [Abstract] [Full Text] [Related]

  • 8. Norfloxacin (MK-0366, AM-715): in vitro activity and cross-resistance with other organic acids including quality control limits for disk diffusion testing.
    Jones RN, Barry AL.
    Diagn Microbiol Infect Dis; 1983 Jun; 1(2):165-72. PubMed ID: 6232084
    [Abstract] [Full Text] [Related]

  • 9. Antibacterial activity of norfloxacin.
    Norrby SR, Jonsson M.
    Antimicrob Agents Chemother; 1983 Jan; 23(1):15-8. PubMed ID: 6219617
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the antibacterial activity of norfloxacin (MK 0366, AM 715), a new organic acid, with that of other orally absorbed chemotherapeutic agents.
    Gadebusch HH, Shungu DL, Weinberg E, Chung SK.
    Infection; 1982 Jan; 10(1):41-4. PubMed ID: 6461606
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. In vitro antibacterial activity of norfloxacin (MK-0366).
    King A, Warren C, Shannon K, Phillips I.
    Antimicrob Agents Chemother; 1982 Apr; 21(4):604-7. PubMed ID: 6211139
    [Abstract] [Full Text] [Related]

  • 13. Comparative in vitro activity of norfloxacin and seven other antimicrobial agents against clinical isolates from urinary tract infections.
    Esko E, Renkonen OV.
    Scand J Infect Dis; 1985 Apr; 17(1):95-8. PubMed ID: 3158071
    [Abstract] [Full Text] [Related]

  • 14. In vitro antibacterial activity of AM-715, a new nalidixic acid analog.
    Ito A, Hirai K, Inoue M, Koga H, Suzue S, Irikura T, Mitsuhashi S.
    Antimicrob Agents Chemother; 1980 Feb; 17(2):103-8. PubMed ID: 6446258
    [Abstract] [Full Text] [Related]

  • 15. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1989). I. Susceptibility distribution].
    Kumamoto Y, Hirose T, Tanaka N, Hikichi Y, Shigeta S, Shiraiwa Y, Kameoka H, Yoshida H, Ogata M, Tazaki H.
    Jpn J Antibiot; 1995 Sep; 48(9):1131-60. PubMed ID: 7474333
    [Abstract] [Full Text] [Related]

  • 16. The treatment of Pseudomonas aeruginosa urinary tract infections with norfloxacin.
    Leigh DA, Emmanuel FX.
    J Antimicrob Chemother; 1984 May; 13 Suppl B():85-8. PubMed ID: 6234280
    [Abstract] [Full Text] [Related]

  • 17. Laboratory evaluation of enoxacin: comparison with norfloxacin and nalidixic acid.
    Teoh-Chan CH, Cowlishaw A, Eley A, Slater G, Greenwood D.
    J Antimicrob Chemother; 1985 Jan; 15(1):45-52. PubMed ID: 3156113
    [Abstract] [Full Text] [Related]

  • 18. Comparative in vitro activity of norfloxacin against urinary tract pathogens.
    Haase D, Urias B, Harding G, Ronald A.
    Eur J Clin Microbiol; 1983 Jun; 2(3):235-41. PubMed ID: 6224679
    [Abstract] [Full Text] [Related]

  • 19. In vitro antibacterial activity of norfloxacin (MK-0366, AM-715) and other agents against gastrointestinal tract pathogens.
    Shungu DL, Weinberg E, Gadebusch HH.
    Antimicrob Agents Chemother; 1983 Jan; 23(1):86-90. PubMed ID: 6219622
    [Abstract] [Full Text] [Related]

  • 20. In vitro antibacterial activity of norfloxacin compared with eight other antimicrobial agents.
    Body BA, Fromtling RA, Shadomy S, Shadomy HJ.
    Eur J Clin Microbiol; 1983 Jun; 2(3):230-4. PubMed ID: 6224678
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.